" class="no-js "lang="en-US"> Pear Therapeutics - Medtech Alert
Thursday, March 28, 2024
Pear Therapeutics | Pharmtech Focus

Pear Therapeutics

About Pear Therapeutics

Pear Therapeutics

At Pear, our mission is clear: we are pioneers in Prescription Digital Therapeutics, or PDTs. Our cross-functional team operates at the intersection of biotechnology and software technology. Pear discovers, develops, and delivers clinically-validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Every day, we push the boundaries of technology to transform medicine. Pear has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s lead product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through the FDA’s traditional 510(k) pathway while simultaneously reviewed through the FDA’s Software Precertification Pilot Program. For more information, visit us at www.peartherapeutics.com.

Related Story

Prime Therapeutics and Pear Therapeutics Announce First Comprehensive Value-based Agreement for Prescription Digital Therapeutics reSET® and reSET-O® for the Treatment of Substance and Opioid Use Disorders

September 30 2021

More than 20 million Americans struggle with drug addiction while only 10-20% receive treatment. Prime Therapeutics […]